Aptose Biosciences
Biopharmaceutical company focused on the discovery, research and development of novel, first-in-class.
Launch date
Employees
Market cap
€6.0m
Enterprise valuation
(€767k) (Public information from Sep 2024)
Share price
CAD0.53 APS.TO
Toronto Ontario (HQ)
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | - | <1m |
| EBITDA | (26.2m) | (55.2m) | (64.8m) | (42.1m) | (51.9m) | (44.4m) | - |
| Profit | (26.3m) | (55.2m) | (65.4m) | (41.8m) | (51.2m) | (44.8m) | (39.8m) |
| % profit margin | - | - | - | - | - | - | (5213 %) |
| EV / revenue | - | - | - | - | - | - | 25.5x |
| EV / EBITDA | -15.6x | -6.6x | -1.7x | -1.3x | -0.4x | -0.2x | - |
| R&D budget | 16.8m | 29.3m | 46.0m | 28.1m | 36.8m | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
* | N/A | $6.6m | Private Placement non VC |
| N/A | $28.3m | Post IPO Equity | |
* | $20.0m | Post IPO Equity | |
| N/A | $21.3m | Post IPO Equity | |
| N/A | $74.2m | Post IPO Equity | |
* | CAD3.0m | Post IPO Equity | |
* | N/A | CAD8.4m | Post IPO Equity |
* | CAD4.0m | Private Placement non VC | |
* | N/A | $4.4m | Post IPO Equity |
* | CAD10.0m | Post IPO Debt | |
| Total Funding | - | ||
Related Content
Recent News about Aptose Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.